Actemra Biosimilar Approved

(MedPage Today) -- The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA)...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news